Matches in SemOpenAlex for { <https://semopenalex.org/work/W4318485573> ?p ?o ?g. }
- W4318485573 abstract "Abstract Introduction Combined treatment using anti-programmed death-ligand 1 antibody (anti-PD-L1) and platinum-etoposide is the current standard first-line treatment for patients with extensive-stage (ES) small cell lung cancer (SCLC). However, the best treatment for relapsed ES-SCLC after the first-line treatment remains unclear. There are some approved chemotherapeutic agents that can be used against ES-SCLC, and treatment with irinotecan is well established as both, a monotherapy and a combined therapy, in combination with platinum. Therefore, we conduct a phase II study with irinotecan in the second- or later-line setting for patients with ES-SCLC who are previously treated with a combination of anti-PD-L1 and platinum-etoposide. Methods Our study will enroll patients who are diagnosed with ES-SCLC and experienced disease progression after treatment of anti-PD-L1 and platinum-etoposide. Patients will receive irinotecan on days 1, 8, and 15, which will be repeated every 4 weeks. Doses of irinotecan (100/80/60 mg/m 2 ) will be determined according to the type of UGT1A1 gene polymorphism, and the treatment will be discontinued following disease progression, intolerance, withdrawal of patient consent, and based on the investigator’s decision. The primary endpoint of the study is the response rate, and the secondary endpoints are overall survival, progression-free survival, and safety. Discussion Since the present first-line treatment has been changed to combined treatment with anti-PD-L1 and platinum-etoposide, the second- or later-line treatment should be re-evaluated for patients with relapsed SCLC. Irinotecan is a major chemotherapeutic agent used for SCLC. This IRICO study demonstrates and re-evaluates the clinical benefits of irinotecan after combined treatment with anti-PD-L1 and platinum-etoposide for patients with ES-SCLC. Registration details This study was registered in the Japan Registry of Clinical Trials (no. jRCT s071210090) on November 4, 2021." @default.
- W4318485573 created "2023-01-30" @default.
- W4318485573 creator A5000467384 @default.
- W4318485573 creator A5011309423 @default.
- W4318485573 creator A5011490272 @default.
- W4318485573 creator A5021321317 @default.
- W4318485573 creator A5021456775 @default.
- W4318485573 creator A5022121676 @default.
- W4318485573 creator A5022748009 @default.
- W4318485573 creator A5024606605 @default.
- W4318485573 creator A5025473586 @default.
- W4318485573 creator A5027171470 @default.
- W4318485573 creator A5033740484 @default.
- W4318485573 creator A5044883471 @default.
- W4318485573 creator A5046810336 @default.
- W4318485573 creator A5050479290 @default.
- W4318485573 creator A5052317767 @default.
- W4318485573 creator A5053684991 @default.
- W4318485573 creator A5057372019 @default.
- W4318485573 creator A5071159100 @default.
- W4318485573 creator A5074797205 @default.
- W4318485573 creator A5076225179 @default.
- W4318485573 creator A5082056968 @default.
- W4318485573 creator A5082897973 @default.
- W4318485573 creator A5083827752 @default.
- W4318485573 creator A5090446099 @default.
- W4318485573 date "2023-01-30" @default.
- W4318485573 modified "2023-10-16" @default.
- W4318485573 title "Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small-cell lung cancer: protocol of IRICO study" @default.
- W4318485573 cites W1932169383 @default.
- W4318485573 cites W1952431753 @default.
- W4318485573 cites W1959962586 @default.
- W4318485573 cites W1971264126 @default.
- W4318485573 cites W1999879350 @default.
- W4318485573 cites W2019041562 @default.
- W4318485573 cites W2103702213 @default.
- W4318485573 cites W2120435735 @default.
- W4318485573 cites W2158127925 @default.
- W4318485573 cites W2421496331 @default.
- W4318485573 cites W2790768119 @default.
- W4318485573 cites W2888375744 @default.
- W4318485573 cites W2893960509 @default.
- W4318485573 cites W2928432651 @default.
- W4318485573 cites W2977392388 @default.
- W4318485573 cites W3028174234 @default.
- W4318485573 cites W3042222777 @default.
- W4318485573 cites W3121328438 @default.
- W4318485573 cites W4292682948 @default.
- W4318485573 doi "https://doi.org/10.21203/rs.3.rs-2372547/v1" @default.
- W4318485573 hasPublicationYear "2023" @default.
- W4318485573 type Work @default.
- W4318485573 citedByCount "0" @default.
- W4318485573 crossrefType "posted-content" @default.
- W4318485573 hasAuthorship W4318485573A5000467384 @default.
- W4318485573 hasAuthorship W4318485573A5011309423 @default.
- W4318485573 hasAuthorship W4318485573A5011490272 @default.
- W4318485573 hasAuthorship W4318485573A5021321317 @default.
- W4318485573 hasAuthorship W4318485573A5021456775 @default.
- W4318485573 hasAuthorship W4318485573A5022121676 @default.
- W4318485573 hasAuthorship W4318485573A5022748009 @default.
- W4318485573 hasAuthorship W4318485573A5024606605 @default.
- W4318485573 hasAuthorship W4318485573A5025473586 @default.
- W4318485573 hasAuthorship W4318485573A5027171470 @default.
- W4318485573 hasAuthorship W4318485573A5033740484 @default.
- W4318485573 hasAuthorship W4318485573A5044883471 @default.
- W4318485573 hasAuthorship W4318485573A5046810336 @default.
- W4318485573 hasAuthorship W4318485573A5050479290 @default.
- W4318485573 hasAuthorship W4318485573A5052317767 @default.
- W4318485573 hasAuthorship W4318485573A5053684991 @default.
- W4318485573 hasAuthorship W4318485573A5057372019 @default.
- W4318485573 hasAuthorship W4318485573A5071159100 @default.
- W4318485573 hasAuthorship W4318485573A5074797205 @default.
- W4318485573 hasAuthorship W4318485573A5076225179 @default.
- W4318485573 hasAuthorship W4318485573A5082056968 @default.
- W4318485573 hasAuthorship W4318485573A5082897973 @default.
- W4318485573 hasAuthorship W4318485573A5083827752 @default.
- W4318485573 hasAuthorship W4318485573A5090446099 @default.
- W4318485573 hasBestOaLocation W43184855731 @default.
- W4318485573 hasConcept C121608353 @default.
- W4318485573 hasConcept C126322002 @default.
- W4318485573 hasConcept C141071460 @default.
- W4318485573 hasConcept C143998085 @default.
- W4318485573 hasConcept C203092338 @default.
- W4318485573 hasConcept C2776256026 @default.
- W4318485573 hasConcept C2776694085 @default.
- W4318485573 hasConcept C2777701055 @default.
- W4318485573 hasConcept C2778119113 @default.
- W4318485573 hasConcept C2780259306 @default.
- W4318485573 hasConcept C526805850 @default.
- W4318485573 hasConcept C535046627 @default.
- W4318485573 hasConcept C71924100 @default.
- W4318485573 hasConceptScore W4318485573C121608353 @default.
- W4318485573 hasConceptScore W4318485573C126322002 @default.
- W4318485573 hasConceptScore W4318485573C141071460 @default.
- W4318485573 hasConceptScore W4318485573C143998085 @default.
- W4318485573 hasConceptScore W4318485573C203092338 @default.
- W4318485573 hasConceptScore W4318485573C2776256026 @default.
- W4318485573 hasConceptScore W4318485573C2776694085 @default.
- W4318485573 hasConceptScore W4318485573C2777701055 @default.
- W4318485573 hasConceptScore W4318485573C2778119113 @default.